Title page Home News Research Gallery Our Team Team publications Contact Public Information Kudos Service
© J. Poirier 2021
Although there are a few medications designed to improve  memory deficits in AD subjects, none of these treatments halt  or slow down the progression, or delay onset of the disease in a significant manner. At best, the clinical benefits last 6 to 18  months, and only in a modest subset of patients. Our pioneering work on the role of genetic risk factors and biomakers in disease etiology and therapy has allowed us to identify several genetic  variants and a few CSF biomarkers that affect either, the age of  onset, the rate of progression or the quality of the drug response to memory enhancer medications. The most common genetic  defect identified so far involves critical transporters of brain  cholesterol called apolipoprotein E (apoE), J and B , as well as  many of their companion proteins called ABCA1 and ABCA7,  BuChE, FDPS, GGDPS and the so called HMGCR. Using this  unique genetic and proteomic information, we have  characterized the biological functions of these key cholesterol  transporter & modulators in the brain and screened a large  number of chemical entities capable of modulating synaptic  plasticity and restoring brain activity of affected AD subjects. This pioneering work led to the successful identification of several  potent inducer agents which have been tested in pre-clinical  research, one of which in phase 2 trials.  
Research Experience and Opportunities
Research Tools Team Publications  Services and Expertises Team Tools Media Facts Patent Portfolio Team Publication List of key publications describing some of the core discoveries done in the ADGEN unit. Patent Portfolio List of key patents  covering ADGEN research team’s discoveries over the course of the past 20 years.
Since  1989 Franšais Franšais Research